With dust settled on activist attack, Laurence Cooper leaves Ziopharm to a new board
Laurence Cooper has done his part.
In the five years since he left a tenured position at Houston’s MD Anderson Cancer Center to become CEO of Boston-based Ziopharm, he’s steered the small-cap immunotherapy player through patient deaths in trials, clinical holds, short attacks and, most recently, an activist attack on the board.
So when the company has “fantastic news” like an IND clearance for a TCR T cell therapy program, he’s ready to pass on the baton.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.